reports
- Franc Gregori
- Lala Gregorek
Trinity Delta Lighthouse: Scancell
Trinity Delta view: Scancell’s H126 results and recent data read outs showcase the progress achieved. The quality and duration of responses seen in the SCOPE study provide reassurance that iSCIB1+ could shift the standard of care in advanced melanoma if replicated in the registrational trial. Inevitably investor attention is now focused on the likely funding mechanism for the trial, with partnership expected to be one of the principal avenues under consideration. However, we would argue the stre...
Interim Results for the six months ended 31 October 2025
Interim Results for the six months ended 31 October 2025 OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a business update and provides its unaudited financial results for the six-month period to 31 October 2025. Highlights (including post period) DNA ImmunoBody ® iSCIB1+ (SCOPE trial): iSCIB1+, the lead product from Scancell's DNA ImmunoBody® platform, demonstrated potentially best-in-class efficacy and durability, and strong Progression Free ...
- Franc Gregori
- Lala Gregorek
Trinity Delta Lighthouse: Scancell
Trinity Delta view: Scancell’s investment case centres on the potential of the lead oncology programmes from its highly promising ImmunoBody and Moditope “off the shelf” platforms. iSCIB1+ already forms the majority of our current rNPV (51.3%) and this is set to rise as Scancell navigates key de-risking events such as securing the funding for iSCIB1+ to enter this pivotal Phase III study. The quality and duration of responses seen in SCOPE provide reassurance that iSCIB1+ could alter standard of...
Scancell announces FDA clearance of IND application for global Phase 3...
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard of care (SoC) iSCIB1+ shows an interim 24%-point improvement in progression free survival (PFS) over real world SoC and historic controls NOTTINGHAM, United Kingdom, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, announces the U.S. Food and Drug...
- Franc Gregori
- Lala Gregorek
Trinity Delta Lighthouse: Scancell
Trinity Delta view: The data from the SCOPE study of Scancell’s “off the shelf” cancer vaccine SCIB1/iSCIB1+ continue to show a clinically meaningful and commercially relevant improvement over currently achievable treatments. The safety and tolerability also remain attractive, with the iSCIB1+/CPI combination comparable to SoC alone. Positive discussions with regulatory authorities mean investor attention will now focus on the design, timing, and, importantly, funding of the pivotal Phase III re...
Scancell updated Phase 2 data shows continued improvement in progressi...
Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma Progression free survival (PFS) of 74% at 16 months compares favourably to standard of care PFS of 50% at 11.5 months 1 Strong PFS consistent across key subgroups Reaffirms selection of iSCIB1+ and target HLA population for late-stage development Early overall survival (OS) data, most advanced for SCIB1, showing a 14% improvement at 26 months over SoC1 In advanced planning for registrational trials with positive scientific advice from regulato...
CVS Group: 2 directors
Two Directors at CVS Group bought 2,060 shares at between 1,211p and 1,214p. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Scancell: Abundant development opportunities in immuno-oncology
Scancell’s investment case centres on the potential of the lead oncology programmes from its highly promising ImmunoBody and Moditope “off the shelf” platforms. Following the successful outcome from the SCOPE trial, iSCIB1+ has been selected as the optimal ImmunoBody candidate to progress into a potentially registrational trial. Forthcoming discussions with the FDA should define the registrational trial design. Other 2025 catalysts include further SCOPE data, plus early data from the RCC (renal ...
Research Update
Research Update Scancell Holdings plc Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025 Data from SCOPE trial show a potential new benchmark in efficacy, durability, immune responses and safety Progression-free survival (PFS) for iSCIB1+ in target population at 11 months is 78%, compared with historic 12 months PFS of 46% with doublet checkpoint therapy of ipilimumab and nivolumab Development plans for iSCIB1+ accelerated including regulatory and partnering discussions, with randomised studies on path to registration ...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 03 November 2025
* A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: Winvia Entertainment (WVIA.L) the technology-led entertainment business focused on two discrete fast-growing channels, being the large and highly fragment...
Scancell Holdings: 1 director
A director at Scancell Holdings bought 3,150,000 shares at 8.9p and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Trinity Delta LIghthouse: Scancell
Trinity Delta view: Scancell continues to advance plans to progress its highly promising ImmunoBody “off-the-shelf” DNA cancer vaccine. Selected candidate iSCIB1+ could offer meaningful benefits to a large, identifiable group of advanced melanoma patients. Critical path meetings with regulators are scheduled, and discussions are also ongoing with potential partners, in order to expeditiously initiate a potentially registrational trial in 2026. Further iSCIB1+ data are expected this year, in addi...
Scancell reports Business Update and Financial Results for the Year En...
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025 NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a business update and provides its final audited financial results for the year ended 30 April 2025. Key highlights (including post-period) DNA ImmunoBody® SCIB1/iSCIB1+ (SCOPE trial) Positive data reported from Phase 2 SCOPE trial shows iSCIB1+ in combination with checkpoint ...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Scancell: SCOPE’ing out iSCIB1+ in advanced melanoma
Data from SCOPE, examining Scancell’s highly promising ImmunoBody “off-the-shelf” DNA cancer vaccine, appear to show that a meaningful, additional benefit can be achieved when added to standard-of-care (SoC) CPIs as a first-line treatment in advanced melanoma. iSCIB1+ has been selected as the candidate for further development; it works in a larger, and easily identifiable, patient group that represents 80% of all advanced melanomas, double that of SCIB1. The benefits of iSCIB1+ will need to be d...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Trinity Delta LIghthouse: Scancell
Trinity Delta view: The positive latest results from the SCOPE study of Scancell’s “off the shelf” cancer vaccine SCIB1/iSCIB1+ are important for three reasons: (1) data consistently show a clinically meaningful and commercially relevant improvement over currently achievable outcomes; (2) the better efficacy can be achieved without worsening SoC safety and tolerability; and (3) the selection of iSCIB1+ should allow a larger group of patients (c 80% of melanoma patients vs c 40% with SCIB1) to be...
Scancell reports Phase 2 data showing strongly improved outcomes in La...
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+ SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type patients, representing 80% of total patients - greatly exceeding the 48-50% for standard of care 12-month progression-free survival also markedly improved, with a 20% increase over standard of care iSCIB1+ Immunobody® selected for future development; planning for registration...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Scancell: Key ImmunoBody clinical data imminent
Scancell’s investment case centres on the lead cancer vaccines from its highly promising ImmunoBody and Moditope “off the shelf” platforms. Key data from two programmes will determine future development plans and define the commercial opportunities. The first, and most important, are the imminent SCOPE trial results: a successful outcome will allow selection of the optimal candidate (SCIB1 or iSCIB1+) to take into a potentially pivotal Phase II/III trial. Later in 2025, early data from the renal...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Cancer vaccine data due soon; Glymab developments too
Trinity Delta view: Upcoming data for Scancell’s highly promising “off the shelf” cancer vaccines (SCIB1/iSCIB1+ and Modi-1) will be key to determine future development plans and better assess the commercial opportunities. First up will likely be SCOPE data, where the key outcome will be selection of the optimal candidate (SCIB1 or iSCIB1+) to take into a potentially pivotal Phase II/III trial. Prior SCIB1 data suggest a commercially relevant and clinically meaningful improvement can be achieved...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 14/04/2025
Our daily digest of news from UK Small Caps @HybridanLLP 14th April 2025 * A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: None Delistings: None What’s ba...
- Franc Gregori
- Lala Gregorek
- Philippa Gardner
Trinity Delta LIghthouse: Scancell
Trinity Delta view: Scancell has the financial resources to progress its two highly promising oncology vaccine platforms (Moditope and ImmunoBody) to key clinical inflection points during 2025. Further data from the ongoing SCOPE trial (Cohort 1 data in mid-2025 and Cohort 3 data in H225), assuming the positive response rates seen in early read-outs is maintained, will help define the optimal vaccine form (SCIB1 or iSCIB1+) and the structure of the potentially pivotal Phase II/III trial. Meanwhi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.